Long-term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis

Pediatr Nephrol. 2007 Jun;22(6):889-92. doi: 10.1007/s00467-006-0426-6. Epub 2007 Feb 3.

Abstract

Recently, there have been reports on the efficacy of low-density lipoprotein (LDL) apheresis (LDL-A) for focal and segmental glomerulosclerosis (FSGS) in pediatric patients. However, there have been few reports on the long-term efficacy of LDL-A for FSGS in such patients. We report here a case of long-term efficacy of LDL-A for FSGS. The patient was a 13-year-old boy with FSGS who presented with steroid-resistant and cyclosporine-resistant nephrotic syndrome and hyperlipidemia. LDL-A was performed 24 times on one year. Following LDL-A, serum concentrations of LDL, very low-density lipoprotein (VLDL), apoprotein B, and vascular endothelial growth factor significantly decreased, and urinary excretion of protein also decreased. In addition, 3 years after LDL-A, the pathology findings on a second renal biopsy had improved. The patient has been in remission from FSGS for 12 years since LDL-A. These findings suggest that LDL-A may be useful in maintaining long-term remission from pediatric FSGS.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Blood Component Removal*
  • Drug Resistance
  • Glomerulosclerosis, Focal Segmental / blood
  • Glomerulosclerosis, Focal Segmental / complications
  • Glomerulosclerosis, Focal Segmental / therapy*
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / complications
  • Hyperlipidemias / therapy
  • Kidney Glomerulus / pathology
  • Lipoproteins, LDL / blood*
  • Male
  • Methylprednisolone / therapeutic use
  • Nephrotic Syndrome / blood
  • Nephrotic Syndrome / etiology
  • Nephrotic Syndrome / therapy
  • Treatment Outcome

Substances

  • Lipoproteins, LDL
  • Methylprednisolone